Current and emerging management options for patients with Morquio A syndrome

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 45-53

  Algahim, Mohamed F ^a   Almassi, G Hossein ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Lysosomal; Mucopolysaccharidosis; Storage disease

Indexed keywords

ANTIBIOTIC AGENT; CHONDROITIN 6 SULFATE; ELOSULFASE ALFA; IDURONATE 2 SULFATASE; KERATAN SULFATE; LEVO IDURONIDASE; LYSOSOME ENZYME; N ACETYLGALACTOSAMINE 6 SULFATASE; PLACEBO;

ADENOIDECTOMY; AIRWAY OBSTRUCTION; AORTA VALVE DISEASE; AORTA VALVE REPLACEMENT; ATLANTOAXIAL SUBLUXATION; BIOACCUMULATION; CERVICAL MYELOPATHY; CONDUCTION DEAFNESS; CORNEA DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DWARFISM; ENDOTRACHEAL INTUBATION; ENZYME DEFICIENCY; ENZYME REPLACEMENT; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMIPLEGIA; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; KYPHOSCOLIOSIS; LIGAMENT DISEASE; MAROTEAUX LAMY SYNDROME; MITRAL VALVE DISEASE; MORQUIO A SYNDROME; MORQUIO SYNDROME; MUSCLE WEAKNESS; NEUROGENIC BLADDER; NEUROGENIC BOWEL; NEUROLOGIC DISEASE; NONHUMAN; OTITIS MEDIA; PERCEPTION DEAFNESS; PHOTOPHOBIA; PIGEON THORAX; QUADRIPLEGIA; RESPIRATORY TRACT INFECTION; REVIEW; SLEEP DISORDERED BREATHING; SPINAL CORD COMPRESSION; STUNTING; TONSILLECTOMY; TRACHEOSTOMY; TYMPANOSTOMY TUBE; VALGUS KNEE; WEAKNESS;

EID: 84875439601     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S24771     Document Type: Review

References (77)

1. Morquio L. Sur une forme de dystrophie osseuse familiale. Archives de Médecine des Infants. 1929;32:129-135. French.
2. Rivera-Colon Y, Schutsky EK, Kita AZ, Garman SC. The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IVA. J Mol Biol. 2012;423(5):736-751.
3. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. 2000;105(1):e10.
4. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101(3):355-358.
5. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999; 105(1-2):151-156.
6. Montano AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30(2):165-174.
7. Davison JE, Kearney S, Horton J, Foster K, Peet AC, Hendriksz CJ. Intellectual and neurological functioning in Morquio syndrome (MPS IVa). J Inherit Metab Dis. Epub January 10, 2012.
8. Tomatsu S, Montano AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12(6):931-945.
9. Langer LO Jr, Carey LS. The roentgenographic features of the KS mucopolysaccharidosis of Morquio (Morquio-Brailsford's disease). Am J Roentgenol Radium Ther Nucl Med. 1966;97(1):1-20.
10. Tong CK, Chen JC, Cochrane DD. Spinal cord infarction remote from maximal compression in a patient with Morquio syndrome. J Neurosurg Pediatr. 2012;9(6):608-612.
11. Dhawale AA, Thacker MM, Belthur MV, Rogers K, Bober MB, Mackenzie WG. The lower extremity in Morquio syndrome. J Pediatr Orthop. 2012;32(5):534-540.
12. Oncag G, Ertan Erdinc AM, Cal E. Multidisciplinary treatment approach of Morquio syndrome (mucopolysaccharidosis type IVA). Angle Orthod. 2006;76(2):335-340.
13. Svensson O, Aaro S. Cervical instability in skeletal dysplasia. Report of 6 surgically fused cases. Acta Orthop Scand. 1988;59(1):66-70.
14. Ransford AO, Crockard HA, Stevens JM, Modaghegh S. Occipitoatlanto-axial fusion in Morquio-Brailsford syndrome. A ten-year experience. J Bone Joint Surg Br. 1996;78(2):307-313.
15. Theroux MC, Nerker T, Ditro C, Mackenzie WG. Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr Anaesth. 2012;22(9):901-907.
16. Walker RW. Management of the difficult airway in children. J R Soc Med. 2001;94(7):341-344.
17. Bartz HJ, Wiesner L, Wappler F. Anaesthetic management of patients with mucopolysaccharidosis IV presenting for major orthopaedic surgery. Acta Orthop Scand. 1999;43(6):679-683.
18. Pagel PS, Almassi GH. Perioperative implications of Morquio syndrome in a 31-year-old woman undergoing aortic valve replacement. J Cardiothorac Vasc Anesth. 2009;23(6):855-857.
19. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996;19(3):357-365.
20. Braunlin EA, Harmatz PR, Scarpa M, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34(6):1183-1197.
21. Engle J, Safi HJ, Abbassi O, et al. Mucopolysaccharidosis presenting as pediatric multiple aortic aneurysm: first reported case. J Vasc Surg. 1997;26(4):704-710.
22. Factor SM, Biempica L, Goldfischer S. Coronary intimal sclerosis in Morquio's syndrome. Virchows Arch A Pathol Anat Histol. 1978; 379(1):1-10.
23. Metcalf JA, Linders B, Wu S, et al. Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression. Mol Genet Metab. 2010;99(4):396-407.
24. Tan CT, Schaff HV, Miller FA Jr, Edwards WD, Karnes PS. Valvular heart disease in four patients with Maroteaux-Lamy syndrome. Circulation. 1992;85(1):188-195.
25. Diaz JH, Belani KG. Perioperative management of children with mucopolysaccharidoses. Anesth Analg. 1993;77(6):1261-1270.
26. John RM, Hunter D, Swanton RH. Echocardiographic abnormalities in type IV mucopolysaccharidosis. Arch Dis Child. 1990;65(7):746-749.
27. Barry MO, Beardslee MA, Braverman AC. Morquio's syndrome: severe aortic regurgitation and late pulmonary autograft failure. J Heart Valve Dis. 2006;15(6):839-842.
28. Nicolini F, Corradi D, Bosio S, Gherli T. Aortic valve replacement in a patient with morquio syndrome. Heart Surg Forum. 2008; 11(2):E96-E98.
29. Neufeld EF. Enzyme replacement therapy - a brief history. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.
30. Deduve C. From cytases to lysosomes. Fed Proc. 1964;23:1045-1049.
31. Cohn ZA, Ehrenreich BA. The uptake, storage, and intracellular hydrolysis of carbohydrates by macrophages. J Exp Med. 1969; 129(1):201-225.
32. Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v49-v59.
33. Giugliani R, Rojas VM, Martins AM, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. 2009;96(1):13-19.
34. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182-188.
35. Muenzer J, Wraith JE, Beck M, et al. A Phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465-473.
36. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148(4):533-539.
37. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzymereplacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115(6):e681-e689.
38. Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144(5):574-580.
39. McGill JJ, Inwood AC, Coman DJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age - a sibling control study. Clin Genet. 2010;77(5):492-498.
40. Wang RY, Cambray-Forker EJ, Ohanian K, et al. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol Genet Metab. 2009;98(4):406-411.
41. Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2010;125(1):e183-e187.
42. Tylki-Szymanska A, Jurecka A, Zuber Z, Rozdzynska A, Marucha J, Czartoryska B. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr. 2012;101(1):e42-e47.
43. Tomatsu S, Montano AM, Gutierrez M, et al. Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine--6-sulfate sulfatase. Mol Genet Metab. 2007;91(1):69-78.
44. Rodriguez A, Espejo AJ, Hernandez A, et al. Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine--6-sulfate sulfatase produced in Escherichia coli BL21. J Ind Microbiol Biotechnol. 2010;37(11):1193-1201.
45. Tomatsu S, Montano AM, Ohashi A, et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet. 2008;17(6):815-824.
46. Dunder U, Kaartinen V, Valtonen P, et al. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J. 2000;14(2):361-367.
47. Vogler C, Levy B, Grubb JH, et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A. 2005;102(41):14777-14782.
48. Roces DP, Lullmann-Rauch R, Peng J, et al. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study. Hum Mol Genet. 2004;13(18):1979-1988.
49. BioMarin Pharmaceuticals Inc. A Phase I/II, Multicenter, Open-Label, Dose escalation study to evaluate the safety, tolerability, and efficacy of bmn 110 in subjects with mucopolysaccharidosis type IVA. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2009 [updated July 15, 2011]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00884949. NLM identifier: NCT00884949. Accessed January 7, 2013.
50. BioMarin Pharmaceuticals Inc. A double-blind study to evaluate the efficacy and safety of BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A syndrome). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 6, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01275066. NLM identifier: NCT01275066. Accessed January 7, 2013.
51. BioMarin Pharmaceuticals Inc. Long-term efficacy and safety extension study of BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A syndrome). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated September 18, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01415427. NLM identifier: NCT01415427. Accessed January 7, 2013.
52. BioMarin Pharmaceuticals Inc. Study of BMN 110 in pediatric patients < 5 years of age with mucopolysaccharidosis IVA (Morquio A syndrome). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated September 18, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01515956. NLM identifier: NCT01515956. Accessed January 7, 2013.
53. BioMarin Pharmaceuticals Inc. A study to evaluate the long-term efficacy and safety of BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A syndrome). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated May 10, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01242111. NLM identifier: NCT01242111. Accessed January 7, 2013.
54. Martell L, Lau K, Mei M, Burnett V, Decker C, Foehr ED. Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers. Orphanet J Rare Dis. 2011;6:84.
55. Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science. 1968;162(3853):570-572.
56. Di Ferrante N, Nichols BL, Donnelly PV, Neri G, Hrgovcic R, Berglund RK. Induced degradation of glycosaminoglycans in Hurler's and Hunter's syndromes by plasma infusion. Proc Natl Acad Sci U S A. 1971;68(2):303-307.
57. Knudson AG Jr, Di Ferrante N, Curtis JE. Effect of leukocyte transfusion in a child with type II mucopolysaccharidosis. Proc Natl Acad Sci U S A. 1971;68(8):1738-1741.
58. Hobbs JR, Hugh-Jones K, Barrett AJ, et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2(8249):709-712.
59. Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol. 2010;47(1):59-69.
60. Peters C, Steward CG; National Marrow Donor Program; International Bone Marrow Transplant Registry; Working Party on Inborn Errors, European Bone Marrow Transplant Group. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. Feb 2003;31(4):229-239.
61. Wynn RF, Wraith JE, Mercer J, et al. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr. 2009;154(4):609-611.
62. Muenzer J, Wraith JE, Clarke LA. International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. Jan 2009;123(1):19-29.
63. Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet. 1993;46(2):209-218.
64. Souillet G, Guffon N, Maire I, et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003; 31(12):1105-1117.
65. Tanaka A, Okuyama T, Suzuki Y, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab. 2012;107(3):513-520.
66. Prasad VK, Mendizabal A, Parikh SH, et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood. 2008;112(7):2979-2989.
67. Lee V, Li CK, Shing MM, et al. Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant. 2000;26(4):455-458.
68. Belinson S, Mauger Rothenberg B, Chopra R, Aronson N. Future Research Needs for Hematopoietic Stem-Cell Transplantation in the Pediatric Population: Identification of Future Research Needs From Comparative Effectiveness Review No 48. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012.
69. Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med. 2004;350(19):1960-1969.
70. Wynn RF, Mercer J, Page J, Carr TF, Jones S, Wraith JE. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr. 2009;154(1):135-139.
71. Mentzer WC, Packman S, Wara W, Morton C. Successful bone marrow transplant in a child with sickle cell anemia and Morquio's disease. Blood. 1990;76:69a.
72. Johnson FL, Mentzer WC, Kalinyak KA, Sullivan KM, Abboud MR. Bone marrow transplantation for sickle cell disease. The United States experience. Am J Pediatr Hematol Oncol. 1994;16(1):22-26.
73. Mah CS, Falk DJ, Germain SA, et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther. 2010;18(3):502-510.
74. Mah C, Fraites TJ Jr, Cresawn KO, Zolotukhin I, Lewis MA, Byrne BJ. A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Mol Ther. 2004;9(3):458-463.
75. Cresawn KO, Fraites TJ, Wasserfall C, et al. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II. Hum Gene Ther. 2005;16(1):68-80.
76. Sun B, Zhang H, Bird A, Li S, Young SP, Koeberl DD. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. J Gene Med. 2009;11(10):913-920.
77. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 2011;12(5):301-315.